Table 1 Multivariable Cox regression analysis of factors prognostic for patient survivala

From: JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma

Factors

Overall survival

Event-free survival

HR (95% CI)

p-value

HR (95% CI)

p-value

High JMJD6 expression (median level as the cut off)

1.87 (1.16–3.02)

0.010

1.52 (1.04–2.20)

0.029

MYCN amplification

3.24 (2.05–5.11)

6.1E–5

1.76 (1.18–2.62)

0.005

Age > 18 months

3.44 (1.88–6.30)

2.6E–05

1.75 (1.19–2.59)

0.005

Stages 3 and 4b

3.14 (1.55–6.35)

0.002

2.38 (1.57–3.62)

4.8E-05

High JMJD6 expression (upper quartile as the cut off)

4.58 (2.15–9.74)

7.8E–5

1.56 (1.06–2.29)

0.024

MYCN amplification

3.19 (2.05–4.96)

2.6E–7

1.82 (1.23–2.68)

0.003

Age > 18 months

3.20 (1.77–5.78)

1.2E–04

1.77 (1.21–2.60)

0.004

Stages 3 and 4b

2.83 (1.41–5.66)

0.003

2.38 (1.57–3.61)

4.4E-05

  1. aThe level of JMJD6 expression was considered high or low in relation to the median or upper quartile level of expression in tumors of the Oberthuer dataset. Hazard ratios were calculated as the antilogs of the regression coefficients in the proportional hazards regression. Multivariable Cox regression analysis was carried out following the inclusion of the four above listed factors into the Cox regression model, and p-value was obtained from two-sided log-rank test
  2. bTumor stage was categorized as favorable (International Neuroblastoma Staging System stages 1, 2, and 4 S) or unfavorable (International Neuroblastoma Staging System stages 3 and 4). Source data are provided as a Source Data file
Back to article page